Subfractions and subpopulations of HDL: An update

Current Medicinal Chemistry

Volumn 21, Issue 25, 2014, Pages 2881-2891

  Rizzo, M ^a,b   Otvos, J ^c   Nikolic, D ^a   Montalto, G ^a   Toth, P P ^b,d   Banach, M ^e  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology ^*  (United States)

^c LIPOSCIENCE INC   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiovascular risk; Electrophoresis; High density lipoprotein; Nuclear magnetic resonance; Proteome; Subclasses; Subfractions; Ultracentrifugation

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR RISK; CLASSIFICATION; DENSITY; ELECTROPHORETIC MOBILITY; HEART PROTECTION; HUMAN; ION MOBILITY SPECTROMETRY; LIPID ANALYSIS; NUCLEAR MAGNETIC RESONANCE; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANIMAL; CARDIOVASCULAR DISEASE; METABOLISM; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, HDL; RISK FACTORS;

EID: 84903456149     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140414103455     Document Type: Article

References (105)

1. Asztalos, B.F.; Schaefer, E.J. High-density lipoprotein subpopulations in pathologic conditions. Am. J. Cardiol., 2003, 91(7A), 12E-17E.
2. Skinner, E.R. High-density lipoprotein subclasses. Curr. Opin. Lipidol., 1994, 5(3), 241-247.
3. Davidson, W.S.; Silva, R.A.; Chantepie, S.; Lagor, W.R.; Chapman, M.J.; Kontush, A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol., 2009, 29(6), 870-876.
4. Kontush, A.; Chantepie, S.; Chapman, M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol., 2003, 23(10), 1881-1888.
5. Lewis, G.F.; Rader, D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res., 2005, 96(12), 1221-1232.
6. Le Goff, W.; Guerin, M.; Chapman, M.J. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol. Ther., 2004, 101(1), 17-38.
7. Guérin, M.; Le Goff, W.; Lassel, T.S.; Van Tol, A.; Steiner, G.; Chapman, M.J. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol., 2001, 21(2), 282-288.
8. Lamarche, B.; Rashid, S.; Lewis, G.F. HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta, 1999, 286(1-2), 145-161.
9. Chapman, M.J.; Goldstein, S.; Lagrange, D.; Laplaud, P.M. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res., 1981, 22(2), 339-358.
10. Anderson, D.W.; Nichols, A.V.; Pan, S.S.; Lindgren, F.T. High density lipoprotein distribution. Resolution and determination of three major components in a normal population sample. Atherosclerosis, 1978, 29(2), 161-179.
11. Cone, J.T.; Segrest, J.P.; Chung, B.H.; Ragland, J.B.; Sabesin, S.M.; Glasscock, A. Computerized rapid high resolution quantitative analysis of plasma lipoproteins based upon single vertical spin centrifugation. J. Lipid Res., 1982, 23(6), 923-935.
12. Kulkarni, K.R.; Marcovina, S.M.; Krauss, R.M.; Garber, D.W.; Glasscock, A.M.; Segrest, J.P. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J. Lipid Res., 1997, 38(11), 2353-2364.
13. Toth, P.P.; Massaro, J.; Jones, S.R.; Griswold, M.; Lirette, S.; Martin, S.; Joshi, P.; D'Agostino, R. Abstract 13843: High-density Lipoprotein Cholesterol Subfractions and Risk for Cardiovascular Events in the Framingham Offspring and Jackson Heart Studies: A Meta-analysis. Circulation, 2013, 128(22 Supplement), A13843.
14. Martin, S.S.; Kulkarni, K.R.; Khokhar, A.; Blaha, M.J.; Joshi, P.H.; Havranek, E.P.; Spertus, J.A.; Jones, S.R. Abstract 16722: HDL Cholesterol Subclasses and Mortality after Acute Myocardial Infarction: The TRIUMPH Prospective Multi-Center Registry. Circulation, 2012, 126(21 Supplement), A16722.
15. Blanche, P.J.; Gong, E.L.; Forte, T.M.; Nichols, A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta, 1981, 665(3), 408-419.
16. Johansson, J.; Carlson, L.A.; Landou, C.; Hamsten, A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler. Thromb., 1991, 11(1), 174-182.
17. Berneis, K.K.; Krauss, R.M. Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid Res., 2002, 43(9), 1363-1379.
18. Camont, L.; Chapman, M.J.; Kontush, A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med., 2011, 17(10), 594-603.
19. Asztalos, B.F.; Sloop, C.H.; Wong, L.; Roheim, P.S. Twodimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim. Biophys. Acta, 1993, 1169(3), 291-300.
20. Freeman, L.A. Native-native 2D gel electrophoresis for HDL subpopulation analysis. Methods Mol. Biol., 2013, 1027, 353-367.
21. Asztalos, B.F.; Collins, D.; Cupples, L.A.; Demissie, S.; Horvath, K.V.; Bloomfield, H.E.; Robins, S.J.; Schaefer, E.J. Value of highdensity lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler. Thromb. Vasc. Biol., 2005, 25(10), 2185-2191.
22. Asztalos, B.F.; Cupples, L.A.; Demissie, S.; Horvath, K.V.; Cox, C.E.; Batista, M.C.; Schaefer, E.J. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol., 2004, 24(11), 2181-2187.
23. Cheung, M.C.; Albers, J.J. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J. Lipid Res., 1982, 23(5), 747-753.
24. Rosenson, R.S.; Brewer, H.B., Jr.; Chapman, M.J.; Fazio, S.; Hussain, M.M.; Kontush, A.; Krauss, R.M.; Otvos, J.D.; Remaley, A.T.; Schaefer, E.J. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem., 2011, 57(3), 392-410.
25. Musunuru, K.; Orho-Melander, M.; Caulfield, M.P.; Li, S.; Salameh, W.A.; Reitz, R.E.; Berglund, G.; Hedblad, B.; Engstrom, G.; Williams, P.T.; Kathiresan, S.; Melander, O.; Krauss, R.M. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler. Thromb. Vasc. Biol., 2009, 29(11), 1975-1980.
26. Hoefner, D.M.; Hodel, S.D.; O'Brien, J.F.; Branum, E.L.; Sun, D.; Meissner, I.; McConnell, J.P. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin. Chem., 2001, 47(2), 266-274.
27. Kucera, M.; Oravec, S.; Hirnerova, E.; Huckova, N.; Celecova, Z.; Gaspar, L.; Banach, M. Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison Between Indicators of Plasma Atherogenicity: A Pilot Study. Angiology, 2013. [Epub ahead of print].
28. Oravec, S.; Dukat, A.; Gavornik, P.; Kucera, M.; Gruber, K.; Gaspar, L.; Rizzo, M.; Toth, P.P.; Mikhailidis, D.P.; Banach, M. Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. Is there a need to change our approach to diagnosing dyslipidemia? Curr. Med. Chem., 2014. [Epub ahead of print].
29. Otvos, J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin. Lab., 2002, 48(3-4), 171-180.
30. Jeyarajah, E.J.; Cromwell, W.C.; Otvos, J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med., 2006, 26(4), 847-870.
31. Lipopscinece. Available from: http://www.liposcience.com/.
32. Tsai, M.Y.; Georgopoulos, A.; Otvos, J.D.; Ordovas, J.M.; Hanson, N.Q.; Peacock, J.M.; Arnett, D.K. Comparison of ultracentrifuga tion and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load. Clin. Chem., 2004, 50(7), 1201-1204.
33. Rizzo, M.; Berneis, K.; Zeljkovic, A.; Vekic, J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin. Lab., 2009, 55(11-12), 421-429.
34. Burchardt, P.; Zurawski, J.; Zuchowski, B.; Kubacki, T.; Murawa, D.; Wiktorowicz, K.; Wysocki, H. Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation. Arch. Med. Sci., 2013, 9(1), 151-158.
35. Yilmaz, N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch. Med. Sci., 2012, 8(1), 138-153.
36. Kontush, A.; Chapman, M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev., 2006, 58(3), 342-374.
37. Kontush, A.; Chapman, M.J. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med., 2006, 3(3), 144-153.
38. Tall, A.R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med., 2008, 263(3), 256-273.
39. Adorni, M.P.; Zimetti, F.; Billheimer, J.T.; Wang, N.; Rader, D.J.; Phillips, M.C.; Rothblat, G.H. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res., 2007, 48(11), 2453-2462.
40. Favari, E.; Calabresi, L.; Adorni, M.P.; Jessup, W.; Simonelli, S.; Franceschini, G.; Bernini, F. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry, 2009, 48(46), 11067-11074.
41. de la Llera-Moya, M.; Drazul-Schrader, D.; Asztalos, B.F.; Cuchel, M.; Rader, D.J.; Rothblat, G.H. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol., 2010, 30(4), 796-801.
42. Gonzalez, M.C.; Toledo, J.D.; Tricerri, M.A.; Garda, H.A. The central type Y amphipathic alpha-helices of apolipoprotein AI are involved in the mobilization of intracellular cholesterol depots. Arch. Biochem. Biophys., 2008, 473(1), 34-41.
43. Miyazaki, M.; Nakano, M.; Fukuda, M.; Handa, T. Smaller discoidal high-density lipoprotein particles form saddle surfaces, but not planar bilayers. Biochemistry, 2009, 48(32), 7756-7763.
44. Rothblat, G.H.; Phillips, M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol., 2010, 21(3), 229-238.
45. Yancey, P.G.; de la Llera-Moya, M.; Swarnakar, S.; Monzo, P.; Klein, S.M.; Connelly, M.A.; Johnson, W.J.; Williams, D.L.; Rothblat, G.H. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem., 2000, 275(47), 36596-36604.
46. Sankaranarayanan, S.; Oram, J.F.; Asztalos, B.F.; Vaughan, A.M.; Lund-Katz, S.; Adorni, M.P.; Phillips, M.C.; Rothblat, G.H. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J. Lipid Res., 2009, 50(2), 275-284.
47. Kontush, A.; Chapman, M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol., 2010, 21(4), 312-318.
48. Zerrad-Saadi, A.; Therond, P.; Chantepie, S.; Couturier, M.; Rye, K.A.; Chapman, M.J.; Kontush, A. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2009, 29(12), 2169-2175.
49. Florentin, M.; Liberopoulos, E.N.; Filippatos, T.D.; Kostara, C.; Tselepis, A.; Mikhailidis, D.P.; Elisaf, M. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin. Pharmacother., 2008, 9(16), 2741-2750.
50. Podrez, E.A. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol., 2010, 37(7), 719-725.
51. Shuhei, N.; Soderlund, S.; Jauhiainen, M.; Taskinen, M.R. Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis., 2010, 9, 104.
52. Ansell, B.J.; Navab, M.; Hama, S.; Kamranpour, N.; Fonarow, G.; Hough, G.; Rahmani, S.; Mottahedeh, R.; Dave, R.; Reddy, S.T.; Fogelman, A.M. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation, 2003, 108(22), 2751-2756.
53. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Ansell, B.J.; Fogelman, A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat. Clin. Prac. Endocrinol. Metab., 2006, 2(9), 504-511.
54. Riwanto, M.; Rohrer, L.; Roschitzki, B.; Besler, C.; Mocharla, P.; Mueller, M.; Perisa, D.; Heinrich, K.; Altwegg, L.; von Eckardstein, A.; Luscher, T.F.; Landmesser, U. Altered activation of endothelial anti-and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation, 2013, 127(8), 891-904.
55. Calabresi, L.; Gomaraschi, M.; Franceschini, G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol., 2003, 23(10), 1724-1731.
56. Toth, P.P. Activation of intracellular signaling systems by highdensity lipoproteins. J. Clin. Lipidol., 2010, 4(5), 376-381.
57. Nofer, J.R.; Assmann, G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med., 2005, 15(7), 265-271.
58. de Souza, J.A.; Vindis, C.; Negre-Salvayre, A.; Rye, K.A.; Couturier, M.; Therond, P.; Chantepie, S.; Salvayre, R.; Chapman, M.J.; Kontush, A. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J. Cell. Mol. Med., 2010, 14(3), 608-620.
59. Kontush, A.; Therond, P.; Zerrad, A.; Couturier, M.; Negre-Salvayre, A.; de Souza, J.A.; Chantepie, S.; Chapman, M.J. Preferential sphingosine-1- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol., 2007, 27(8), 1843-1849.
60. Barter, P.; Kastelein, J.; Nunn, A.; Hobbs, R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis, 2003, 168(2), 195-211.
61. Vekic, J.; Topic, A.; Zeljkovic, A.; Jelic-Ivanovic, Z.; Spasojevic-Kalimanovska, V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin. Biochem., 2007, 40(5-6), 310-316.
62. Otvos, J.D.; Shalaurova, I.; Freedman, D.S.; Rosenson, R.S. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis, 2002, 160(1), 41-48.
63. Stampfer, M.J.; Sacks, F.M.; Salvini, S.; Willett, W.C.; Hennekens, C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N. Engl. J. Med., 1991, 325(6), 373-381.
64. Yu, S.; Yarnell, J.W.; Sweetnam, P.; Bolton, C.H. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis, 2003, 166(2), 331-338.
65. Juárez-Rojas, J.G.; Medina-Urrutia, A.X.; Jorge-Galarza, E.; Caracas-Portilla, N.A.; Posadas-Sánchez, R.; Cardoso-Saldaña, G.C.; Goycochea-Robles, M.V.; Silveira, L.H.; Lino-Pérez, L.; Mas-Oliva, J.; Pérez-Méndez, O.; Posadas-Romero, C. Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. Lupus, 2012, 21(1), 27-35.
66. Rizzo, M.; Vekic, J.; Koulouris, S.; Zeljkovic, A.; Jelic-Ivanovic, Z.; Spasojevic-Kalimanovska, V.; Rini, G.B.; Sakellariou, D.; Pastromas, S.; Mikhailidis, D.P.; Manolis, A.S. Effects of rosiglitazone on fasting and postprandial low-and high-density lipoproteins size and subclasses in type 2 diabetes. Angiology, 2010, 61(6), 584-590.
67. Mackey, R.H.; Kuller, L.H.; Sutton-Tyrrell, K.; Evans, R.W.; Holubkov, R.; Matthews, K.A. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study. Arch. Intern. Med., 2005, 165(5), 510-515.
68. Airan-Javia, S.L.; Wolf, R.L.; Wolfe, M.L.; Tadesse, M.; Mohler, E.; Reilly, M.P. Atheroprotective lipoprotein effects of a niacinsimvastatin combination compared to low-and high-dose simvastatin monotherapy. Am. Heart J., 2009, 157(4), 687.e681-688.
69. The HPS2-THRIVE Trial. Available from: http://www.ctsu.ox. ac.uk/-thrive/.
70. Lavigne, P.M.; Karas, R.H. The current state of niacin in cardiovascular disease prevention: a systematic review and metaregression. J. Am. Coll. Cardiol., 2013, 61(4), 440-446.
71. Walldius, G.; Jungner, I.; Holme, I.; Aastveit, A.H.; Kolar, W.; Steiner, E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study), a prospective study. Lancet, 2001, 358(9298), 2026-2033.
72. van der Steeg, W.A.; Holme, I.; Boekholdt, S.M.; Larsen, M.L.; Lindahl, C.; Stroes, E.S.; Tikkanen, M.J.; Wareham, N.J.; Faergeman, O.; Olsson, A.G.; Pedersen, T.R.; Khaw, K.T.; Kastelein, J.J. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol., 2008, 51(6), 634-642.
73. Nicholls, S.J.; Gordon, A.; Johannson, J.; Ballantyne, C.M.; Barter, P.J.; Brewer, H.B.; Kastelein, J.J.; Wong, N.C.; Borgman, M.R.; Nissen, S.E. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc. Drugs Ther., 2012, 26(2), 181-187.
74. Waksman, R.; Torguson, R.; Kent, K.M.; Pichard, A.D.; Suddath, W.O.; Satler, L.F.; Martin, B.D.; Perlman, T.J.; Maltais, J.A.; Weissman, N.J.; Fitzgerald, P.J.; Brewer, H.B.J.r. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol., 2010, 15(24), 2727-2735.
75. Nissen, S.E.; Tsunoda, T.; Tuzcu, E.M.; Schoenhagen, P.; Cooper, C.J.; Yasin, M.; Eaton, G.M.; Lauer, M.A.; Sheldon, W.S.; Grines, C.L.; Halpern, S.; Crowe, T.; Blankenship, J.C.; Kerensky, R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA, 2003, 290(17), 2292-2300.
76. Nicholls, S.J.; Brewer, H.B.; Kastelein, J.J.; Krueger, K.A.; Wang, M.D.; Shao, M.; Hu, B.; McErlean, E.; Nissen, S.E. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA, 2011, 306(19), 2099-2109.
77. Kastelein, J.J.; van Leuven, S.I.; Burgess, L.; Evans, G.W.; Kuivenhoven, J.A.; Barter, P.J.; Revkin, J.H.; Grobbee, D.E.; Riley, W.A.; Shear, C.L.; Duggan, W.T.; Bots, M.L.; Investigators, R. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med., 2007, 356(16), 1620-1630.
78. Barter, P.J.; Caulfield, M.; Eriksson, M.; Grundy, S.M.; Kastelein, J.J.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.C.; Waters, D.D.; Shear, C.L.; Revkin, J.H.; Buhr, K.A.; Fisher, M.R.; Tall, A.R.; Brewer, B. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med., 2007, 357(21), 2109-2122.
79. Klein, R.L.; Carter, R.E.; Jenkins, A.J.; Lyons, T.J.; Baker, N.L.; Gilbert, G.E.; Virella, G.; Lopes-Virella, M.F. DCCT/EDIC Research Group. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J. Diabetes Complications, 2011, 25(2), 73-82.
80. Fendler, W.; Rizzo, M.; Borowiec, M.; Malachowska, B.; Antosik, K.; Szadkowska, A.; Banach, M.; Urbanska-Kosinska, M.; Szopa, M.; Malecki, M.; Mlynarski, W. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol., 2014. [Epub ahead of print].
81. Tejero, M.E.; Voruganti, V.S.; Cai, G.; Cole, S.A.; Laston, S.; Wenger, C.R.; Mac, C., J.W.; Dyke, B.; Devereux, R.; Ebbesson, S.O.; Fabsitz, R.R.; Howard, B.V.; Comuzzie, A.G. Pleiotropic effects on subclasses of HDL, adiposity, and glucose metabolism in adult Alaskan Eskimos. Am. J. Hum. Biol., 2010, 22(4), 444-448.
82. Castelli, W.P.; Garrison, R.J.; Wilson, P.W.; Abbott, R.D.; Kalousdian, S.; Kannel, W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 1986, 256(20), 2835-2838.
83. Shah, P.K.; Kaul, S.; Nilsson, J.; Cercek, B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation, 2001, 104(19), 2376-2383.
84. de Beer, M.C.; Durbin, D.M.; Cai, L.; Mirocha, N.; Jonas, A.; Webb, N.R.; de Beer, F.C.; van Der Westhuyzen, D.R. Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI. J. Biol. Chem., 2001, 276(19), 15832-15839.
85. Hedrick, C.C.; Castellani, L.W.; Wong, H.; Lusis, A.J. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions. J. Lipid Res., 2001, 42(4), 563-570.
86. Shah, P.K.; Kaul, S.; Nilsson, J.; Cercek, B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation, 2001, 104(20), 2498-2502.
87. Barylski, M.; Mayszko, J.; Rysz, J.; Myliwiec, M.; Banach, M. Lipids, blood pressure, kidney -what was new in 2011? Arch. Med. Sci., 2011, 7(6), 1055-1066.
88. Otocka-Kmiecik, A.; Mikhailidis, D.P.; Nicholls, S.J.; Davidson, M.; Rysz, J.; Banach, M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res., 2012, 51(4), 314-324.
89. Katsiki, N.; Nikolic, D.; Montalto, G.; Banach, M.; Mikhailidis, D.P.; Rizzo, M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des., 2013, 19(17), 3124-3131.
90. Mora, S.; Szklo, M.; Otvos, J.D.; Greenland, P.; Psaty, B.M.; Goff, D.C., Jr.; O'Leary, D.H.; Saad, M.F.; Tsai, M.Y.; Sharrett, A.R. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2007, 192(1), 211-217.
91. Otvos, J.D.; Collins, D.; Freedman, D.S.; Shalaurova, I.; Schaefer, E.J.; McNamara, J.R.; Bloomfield, H.E.; Robins, S.J. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation, 2006, 113(12), 1556-1563.
92. Parish, S.; Offer, A.; Clarke, R.; Hopewell, J.C.; Hill, M.R.; Otvos, J.D.; Armitage, J.; Collins, R.; Heart Protection Study Collaborative, G. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation, 2012, 125(20), 2469-2478.
93. Mora, S.; Glynn, R.J.; Ridker, P.M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation, 2013, 128(11), 1189-1197.
94. Mackey, R.H.; Greenland, P.; Goff, D.C., Jr.; Lloyd-Jones, D.; Sibley, C.T.; Mora, S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol., 2012, 60(6), 508-516.
95. Gordon, S.; Durairaj, A.; Lu, J.L.; Davidson, W.S. High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality. Curr. Cardiovasc. Risk Rep., 2010, 4(1), 1-8.
96. Mackness, B.; Mackness, M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv. Exp. Med. Biol., 2010, 660: 143-151.
97. Deakin, S.; Moren, X.; James, R.W. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler. Thromb. Vasc. Biol., 2007, 27(5), 1146-1152.
98. Huang, Y.; Wu, Z.; Riwanto, M.; Gao, S.; Levison, B.S.; Gu, X.; Fu, X.; Wagner, M.A.; Besler, C.; Gerstenecker, G.; Zhang, R.; Li, X.M.; DiDonato, A.J.; Gogonea, V.; Tang, W.H.; Smith, J.D.; Plow, E.F.; Fox, P.L.; Shih, D.M.; Lusis, A.J.; Fisher, E.A.; DiDonato, J.A.; Landmesser, U.; Hazen, S.L. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest., 2013, 123(9), 3815-3828.
99. Raterman, H.G.; Levels, H.; Voskuyl, A.E.; Lems, W.F.; Dijkmans, B.A.; Nurmohamed, M.T. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann. Rheum. Dis., 2013, 72(4), 560-565.
100. Gordon, S.M.; Deng, J.; Tomann, A.B.; Shah, A.S.; Lu, L.J.; Davidson, W.S. Multi-dimensional co-separation analysis reveals protein-protein interactions defining plasma lipoprotein subspecies. Mol. Cell. Proteomics, 2013, 12(11), 3123-3134.
101. Yassine, H.; Borges, C.R.; Schaab, M.R.; Billheimer, D.; Stump, C.; Reaven, P.; Lau, S.S.; Nelson, R. Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin. Appl., 2013, 7(7-8), 528-540.
102. Barylski, M.; Toth, P.P.; Nikolic, D.; Banach, M.; Rizzo, M.; Montalto, G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract. Res. Clin. Endocrinol. Metab., 2014. doi: 10.1016/j.beem.2013.1011.1001.
103. Serban, C.; Muntean, D.; Mikhailids, D.P.; Toth, P.P.; Banach, M. Dysfunctional HDL: The journey from savior to slayer. Clin. Lipidol., 2014, 9(1), 49-59.
104. Banach, M.; Serban, C.; Aronow, W.S.; Rysz, J.; Dragan, S.; Lerma, E.V.; Apetrii, M.; Covic, A. Lipid, blood pressure and kidney update 2013. Int. Urol. Nephrol., 2014. [Epub ahead of print].
105. Toth, P.P.; Barylski, M.; Nikolic, D.; Rizzo, M.; Montalto, G.; Banach, M. Should low high-density lipoprotein cholesterol (HDLC) be treated? . Best Pract. Res. Clin. Endocrinol. Metab., 2014. doi: 10.1016/j.beem.2013.1011.1002.